Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

Study identifies another strategy for normalizing tumor blood supply

Manipulating levels of nitric oxide (NO), a gas involved in many biological processes, may improve the disorganized network of blood vessels supplying tumors, potentially improving the effectiveness of radiation and chemotherapy.

21 Feb 2008

New way to grow blood vessels

Researchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation.

21 Feb 2008

VEGF-B helps nerve cells cheat death without unwanted side effects

The prototypical member of the VEGF family of proteins, VEGF, has recently been shown to protect cells in the nervous system from death and degeneration.

8 Feb 2008

Kidney cancer drug attacks a major type of acute myeloid leukemia

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.

30 Jan 2008

A new significance of LVD and angiogenic MVD is identified in human primary SCRC

Lymphangiogenesis and angiogenesis are critical processes for tumor growth, invasion and metastasis.

17 Jan 2008

Study shows that antiangiogenic agent delays progression of advanced breast cancer

The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

28 Dec 2007

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Cancer stem cells may be at the root of brain tumors

Stem cells -- popularly known as a source of biological rejuvenation -- may play harmful roles in the body, specifically in the growth and spread of cancer. Amongst the wildly dividing cells of a tumor, scientists have located cancer stem cells.

27 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Epigenomic test that could improve treatment for specific gastric cancers

A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome.

12 Dec 2007

Cancer cell line developed that is resistant to new cancer therapy

A cancer cell line that is resistant to one of the newest classes of cancer treatments has been developed by researchers who already are using it to determine what else to give patients when this happens.

12 Dec 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Discovery of key pathway, potential drug targets in autoinflammatory disease

Molecular biologists at Jefferson's Kimmel Cancer Center in Philadelphia have detailed the cascade of cellular events behind some potentially dangerous autoinflammatory diseases.

13 Nov 2007

Antibody might help starve cancerous tumors

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell, a publication of Cell Press.

2 Nov 2007